EPO and breast carcinoma: Similarly, the Breast Cancer Erythropoietin Trial (BEST) examining the use of rhEPO in women with metastatic breast cancer receiving first-line chemotherapy was terminated prematurely owing to an observed higher mortality in the rhEPO group (Leyland-Jones, 2003).